Home  »  Companies   »  AstraZeneca PLC (NASDAQ: AZN) Stock: Now At 26.89%...

AstraZeneca PLC (NASDAQ: AZN) Stock: Now At 26.89% Gain Since Low, This Stock Just Hasn’t Warmed Up

AstraZeneca PLC (NASDAQ:AZN) price closed lower on Monday, September 18, dropping -2.14% below its previous close.

A look at the daily price movement shows that the last close reads $68.27, with intraday deals fluctuated between $68.20 and $68.90. The company’s P/E ratio in the trailing 12-month period read 33.83. Taking into account the 52-week price action we note that the stock hit a 52-week high of $76.56 and 52-week low of $52.65. The stock subtracted -3.34% on its value in the past month.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free

AstraZeneca PLC, which has a market valuation of $204.83 billion. The company stock has a Forward Dividend ratio of 1.45, while the dividend yield is 2.17%. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Analysts tracking AZN have forecast the quarterly EPS to grow by 0.85 per share this quarter, while the same analysts predict the annual EPS to hit $3.69 for the year 2023 and up to $5.69 for 2024. In this case, analysts estimate an annual EPS growth of 10.80% for the year and 54.20% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $11.67 billion, with the likely lows of $11.52 billion and highs of $11.99 billion. The average estimate suggests sales growth for the quarter will likely rise by 7.00% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $45.63 billion for the company’s annual revenue in 2023. Per this projection, the revenue is forecast to grow 2.90% above that which the company brought in 2023.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give AZN a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 32 analysts have assigned AZN a recommendation rating as follows: 6 rate it as a Hold; 24 advise Buy while 2 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the AstraZeneca PLC (AZN) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 2.52. The overview shows that AZN’s price is at present -1.84% off the SMA20 and -2.56% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 43.07, with weekly volatility standing at 1.34%. The indicator jumps to 1.20% when calculated based on the past 30 days. AstraZeneca PLC (NASDAQ:AZN)’s beta value is holding at 0.51, while the average true range (ATR) indicator is currently reading 1.15. Considering analysts have assigned the stock a price target range of $65.08-$106.75 as the low and high respectively, we find the trailing 12-month average consensus price target to be $83.94. Based on this estimate, we see that current price is roughly 2.59% off the estimated low and -59.78% off the forecast high. Investors will no doubt be excited to see the share price fall to $83.00, which is the median consensus price, and at that level AZN would be -24.23% from current price.

Turning out attention to how the AstraZeneca PLC stock has performed in comparison to its peers in the industry, here’s what we find: AZN’s stock is -2.14% on the day and 14.91% in the past 12 months, while Eli Lilly and Company (LLY) traded -0.84% in the last session and was positioned 84.45% up on its price 12 months ago. Another comparison is with Biogen Inc. (BIIB) whose stock price was down -0.51% in the last trading session, and has flourished 24.20% over the past year. Also, Johnson & Johnson (JNJ) showed down trend of -0.02% while its price kept floating at -2.21% over the past year. As for AstraZeneca PLC, the P/E ratio stands at 33.83 lower than that of Eli Lilly and Company’s at 79.30 and Biogen Inc.’s 13.81. Elsewhere in the market, the S&P 500 Index has rallied 0.05% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.06%.

An analysis of the AstraZeneca PLC (NASDAQ:AZN) stock in terms of its daily trading volume indicates that the 3-month average is 5.22 million. However, this figure increases on the past 10-day timeline to an average of 4.3 million.

Current records show that the company has 3.10B in outstanding shares. The insiders’ percentage holdings are 0.50% of outstanding shares while the percentage share held by institutions stands at 17.90%. The stats also highlight that short interest as of Aug 30, 2023, stood at 7.33 million shares, which puts the short ratio at the time at 1.67. From this we can glean that short interest is 0.24% of company’s current outstanding shares. Notably, we see that shares short in August rose slightly given the previous month’s figure stood at 6.05 million. But the -1.46% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.